Multicenter prospective phase II study of sunitinib in non-clear cell type renal cell carcinoma

被引：0
|
作者：
Lee, J.
Ahn, J.
Lim, H.
Lee, S.
Kim, T.
Lee, D.
Cho, Y. M.
Hong, J.
Kim, C.
Ahn, H.
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[5] Seoul Natl Univ, Dept Internal Med, Seoul, South Korea
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea
[7] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 07期
关键词：
D O I：
10.1200/jco.2011.29.7_suppl.325
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
325
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma
    Naik, Priyanka
    Dudipala, Harshitha
    Chen, Yu-Wei
    Rose, Brent
    Bagrodia, Aditya
    Mckay, Rana R.
    THERAPEUTIC ADVANCES IN UROLOGY, 2024, 16
  • [32] Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.
    Koshkin, Vadim S.
    Barata, Pedro C.
    Vogelzang, Nicholas J.
    Pal, Sumanta K.
    Hsu, Joann
    Allman, Kimberly D.
    Gilligan, Timothy D.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Non-Clear Cell Renal Cell Carcinoma, Part 1: Histology
    Valenca, Loana B.
    Hirsch, Michelle S.
    Choueiri, Toni K.
    Harshman, Lauren C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 308 - 313
  • [34] Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options
    Ahrens, Marit
    Scheich, Sebastian
    Hartmann, Arndt
    Bergmann, Lothar
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 128 - 135
  • [35] Non-Clear Cell Renal Cell Carcinoma, Part 2: Therapy
    Valenca, Loana B.
    Hirsch, Michelle S.
    Choueiri, Toni K.
    Harshman, Lauren C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (06) : 383 - 391
  • [36] Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
    Sepe, Pierangela
    Ottini, Arianna
    Pircher, Chiara Carlotta
    Franza, Andrea
    Claps, Melanie
    Guadalupi, Valentina
    Verzoni, Elena
    Procopio, Giuseppe
    CANCERS, 2021, 13 (15)
  • [37] Targeted therapies and the treatment of non-clear cell renal cell carcinoma
    Bellmunt, J.
    Dutcher, J.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1730 - 1740
  • [38] Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology.
    Koh, Youngil
    Kim, Ji Yeon
    Lim, Ho Yeong
    Ahn, Jin-Hee
    Lee, Jae-Lyun
    Rha, Sun Young
    Kim, YuJung
    Kim, Tae Min
    Lee, Se-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Updates in the Systemic Therapy Options for Clear Cell and Non-Clear Cell Renal Cell Carcinoma
    Spiess, Philippe E.
    Johnstone, Peter A. S.
    Jonasch, Eric
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5):
  • [40] A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
    Hutson, Thomas E.
    Michaelson, M. Dror
    Kuzel, Timothy M.
    Agarwal, Neeraj
    Molina, Ana M.
    Hsieh, James J.
    Vaishampayan, Ulka N.
    Xie, Ran
    Bapat, Urmi
    Ye, Weifei
    Jain, Rohit K.
    Fishman, Mayer N.
    EUROPEAN UROLOGY, 2021, 80 (02) : 162 - 170
12345